Tuesday, February 16, 2010 8:00 am - 7:00 pm (Eastern Time)
Preliminary
Agenda
Please visit this page for presentation schedule updates. If you are interested in more information or conference sponsorship, please contact us.
7:00 - 8:00 |
Registration & Continental Breakfast Welcome & Introductions to the Stem Cell Summit |
8:00
- 8:10 |
Overall
Welcome & Introduction to the 5th Annual Stem Cell
Summit—A New York Perspective on Stem Cell Research
and Development |
 |
Maria K.
Mitchell, PhD |
Founding president of AMDeC, a Consortium of 28 of New York's preeminent medical schools, academic health centers and medical research institutions dedicated to advancing the biomedical research sector in New York. |
8:10
- 8:30 | The
State of MSC's in 2010 |
 |
Arnold
Caplan, PhD |
Professor of Biology and General Medicine Sciences (Oncology) Case Western Reserve University |
8:30
- 8:35 |
Welcome
& Meeting Overview |
 |
Robin
R. Young, CFA |
President
and Publisher RRY Publications LLC CEO and Co-Founder for PearlDiver Technologies, Inc. |
8:35
- 5:00 |
Parthenogenetic & Embryonic Stem Cells |
8:35
- 8:45 |
International Stem Cell Corp. |
 |
Kenneth Aldrich Chairman,
CEO
& Co-Founder |
International Stem Cell Corp. has developed breakthrough human stem cell lines that promise to eliminate the rejection of transplanted cells by the immune system. It also produces specialized cells and growth media worldwide for therapeutic research. |
8:47
- 8:57 |
Stemina
Biomarker Discovery |
 |
Elizabeth
L.R. Donley,
JD, MBA, MS CEO, Member Board of Directors |
Stemina's innovative cell based assays arise from the strategic convergence of two groundbreaking technologies: stem cells and metabolomics |
8:59-
9:09 |
Celtigen
Therapeutics, LLC |
 |
Angela
M. Christiano,
PhD Professor of Dermatology, Director of Research, Columbia University |
Celtigen is a biotechnology company focused on commercializing its autologous adult dermal stem cell technology for hair follicle regeneration and skin tissue engineering. |
9:11
- 9:21 |
ArunA
Biomedical, Inc. |
 |
Steven
Stice, PhD Chairman and Chief Scientific Officer |
ArunA Biomedical is a pioneer and leader in providing innovative products and services derived from human stem cells. |
|
9:23
- 9:33 |
Aldagen,
Inc. |
 |
Ed
Field President & COO |
Aldagen is a regenerative medicine company developing and commercializing products to treat vascular and degenerative diseases. |
9:35
- 9:45 |
Genzyme
Biosurgery |
 |
Stephen
Potter Senior VP, Corporate Development |
Genzyme is a leader in developing and applying the most advanced technologies in the life sciences. The company is focused on rare inherited disorders, kidney disease, orthopaedics, transplant, cancer, and diagnostic testing. |
9:47
- 9:57 |
Osiris Therapeutics |
 |
C.
Randal Mills,
PhD President, CEO, & Director |
Osiris is the leading stem cell therapeutic company focused on developing products to treat serious medical conditions in the inflammatory, orthopedic and cardiovascular areas. Several products are under development including Prochymal® and Chondrogen®, two formulations of mesenchymal stem cells. |
9:59
- 10:09 |
MaxCyte, Inc. |
 |
Madhusudan
Peshwa, PhD Exec. V.P., Cellular Therapies |
MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. |
10:11
- 10:21 |
AllCells, LLC |
 |
David
Matzilevich,
MD, PhD NECTAR |
AllCells' products include a wide variety of unprocessed and purified normal human blood and bone marrow cells. |
10:23
- 10:33 |
ProChon
Biotech, Ltd. |
 |
Kirk
Andriano, PhD Chief Technology Officer |
ProChon is focused on modulating the fibroblast growth factor system to create more effective solutions for tissue regeneration. |
10:35
- 10:45 |
Pluristem Therapeutics, Inc. |
 |
William
Prather, RPh,
MD Senior VP, Corporate Development |
Pluristem is a biotherapeutics company dedicated to the commercialization of allogeneic cell therapy products, derived from human placenta, for the treatment of several severe ischemic and autoimmune disorders. |
10:47
- 10:57 |
Aastrom Biosciences, Inc. |
 |
Elmar
R. Burchardt,
MD, PhD VP - Medical Affairs |
Aastrom Biosciences, Inc. is developing autologous cell products based on its proprietary Tissue Repair Cell (TRC) technology. |
10:59
- 11:09 |
Gamida Cell Ltd. |
 |
Yael
Margolin, PhD CEO |
Gamida Cell Ltd. is a world leader in stem cell expansion technologies and therapeutic products. |
11:11
- 11:21 |
Stematix |
 |
David
C. Bonner Chairman & CEO |
Stematix is a regenerative medicine technology and solutions provider positioned to accelerate safe and effective global use of stem cell therapies. |
11:23
- 11:33 |
Garnet
BioTherapeutics, Inc. |
 |
Gerri
Henwood CEO |
Garnet is developing the next generation of biomedicines by harnessing the therapeutic potential of the human cell. It is focused on dermal-based regenerative therapy. |
11:35
- 11:45 |
Mesoblast Limited |
 |
Michael
Schuster Vice President |
Mesoblast Limited is an Australian biotechnology company committed to the development of novel treatments for orthopaedic conditions, including the commercialisation of unique adult stem cells to regenerate and repair bone and cartilage. |
|
1:45 - 1:55 |
Lonza |
 |
David
Smith,
VP, Cell Therapy and Biotherapeutic Media |
Lonza offers the life sciences market a full range of bioresearch products, development services and manufacturing for functional and active ingredients. |
1:57 - 2:07 |
TiGenix NV |
 |
Gil Beyen, Managing Director & CEO |
TiGenix focuses on ‘Regenerating Motion‘. The company is exploiting the power of regenerative medicine to repair damaged and arthritic joints. Its lead product ChondroCelect® received European approval as the first ATMP. |
2:09- 2:19 |
Cellerix Living Medicines |
 |
Edwardo
Bravo, MBA CEO |
Cellerix is leading the development of a new generation of treatments using expanded adult stem cells from adipose tissue (eASCs). |
2:21-
2:31 |
Athersys,
Inc. |
 |
William (B.J.) Lehmann,
JD
President & COO |
Athersys is a clinical-stage biopharma company with a growing pipeline of highly differentiated therapeutics to treat significant and life-threatening diseases. Its lead programs are in the areas of obesity, myocardial infarction and bone marrow transplant. |
2:33-
2:43 |
AlloSource |
 |
Kevin Cmunt
Exec. Vice President |
AlloSource is a non-profit organization founded in 1994 on a promise: to honor and respect the gift of donation by responsibly developing, processing and distributing life-saving and life-enhancing allografts for its communities. |
Tools & Instruments |
2:45
- 2:55 |
Cytori Therapeutics, Inc. |
 |
Tom
Baker Director, Investor Relations |
Cytori Therapeutics, Inc. is a leader in regenerative medicine and cell-based technology utilizing adult stem and regenerative cells derived from adipose tissue. |
2:57
- 3:07 |
Core Dynamics Ltd. |
 |
Sachi
Norman, MD, MBA CEO |
Core Dynamics brings science fiction to life with innovative freezing, thawing and freeze drying technologies for cell, tissue and organ preservation. |
3:09
- 3:19 |
Glycosan
BioSystems, Inc. |
 |
Dr.
William P. Tew Co-Founder, President & CEO |
Glycosan BioSystems' patent-pending Extracel™ technology was developed by the Center for Therapeutic Biomaterials at the University of Utah. |
3:21
- 3:31 |
Cardiogenesis
Corp. |
 |
Paul
McCormick Executive Chairman |
Cardiogenesis Corporation is a global leader in products and technologies to treat severe angina pain. Its development initiatives include minimally invasive cardiology products as well as integrated biologic and laser delivery systems. |
3:33
- 3:43 |
Harvest Technologies Corp. |
 |
Gary
D. Tureski Co-Founder & President |
Harvest seeks to Improve patient outcomes by enhancing the body's normal healing process using adult stem cells and growth factors. |
3:45
- 3:55 |
Vet-Stem, Inc. |
 |
Robert J. Harman, DVM, MPVM CEO & Founder |
Vet-Stem's regenerative medicine uses a concentrated form of autologous, adipose-derived adult stem cells to treat traumatic and degenerative diseases within the veterinary market. |
3:57
- 4:07 |
TxCell |
 |
Frederic
Hammel
CEO |
TxCell is a biotech company developing investigational products in a new class of autologous cellular immunotherapies based on type 1T regulatory lymphocytes (Tr1). |
4:09
- 4:19 |
Progenitor
Cell Therapy, LLC |
 |
Robert
A. Preti, PhD President & Chief Scientific Officer |
Progenitor Cell Therapy is a client-based cell therapy services company that supports the development of cellular therapies. |
4:21
- 4:31 |
BioE Corp. |
 |
Michael
Haider President & CEO |
BioE provides innovative cell biologics technologies for the biomedical industry. |
4:33
- 4:43 |
Tissue Genesis, Inc. |
 |
Stuart
Williams, PhD Chief Science Officer |
Tissue Genesis, Inc. is an emerging highgrowth company in the field of regenerative medicine, using a patient’s own therapeutic cells to coat implants, repair damaged tissue, heal disease, and address other medical concerns. |
4:45 - 4:55 |
INCELL
Corp., LLC |
 |
Mary
Pat Moyer, PhD Founder, President, CEO & CSO |
INCELL manufactures products for cell culture and research applications. |
4:57 - 5:07 |
SpineSmith Partners LP |
 |
Robert
G. Johnson, MD |
SpineSmith designs, develops and markets implants and biologics for surgical fixation, correction and tissue regeneration of the spine. Its technology focuses on the stabilization and treatment of spinal and orthopedic disorders. |
5:09 - 5:19 |
WuXi AppTec |
 |
Garry
Takle,
PhD
Vice President of Philadelphia Operations |
WuXi AppTec provides a seamless, high-quality, single-source approach for the development and testing of biotherapeutics. This single-source strategy can reduce the time to clinic and can significantly decrease the cost of drug development efforts. |
5:20 |
|
|||
|
Networking |
|||